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Abstract
Objective: To determine if intrauterine intraumbilical 
supplementation with amino acids (AA) and glucose can 
improve neonatal outcome of severe growth restricted 
human fetuses (IUGR).
Methods: Prospective pilot study of intrauterine treat-
ment of severe IUGR fetuses [n = 14, 27 weeks of gestation 
(range  23–31)] with cerebroplacental ratio < 1, with long-
term intraumbilical AA and glucose supplementation 
(10% of feto-placental blood volume/day) using a perina-
tal port system alone (n = 5) or combined with hyperbaric 
oxygenation (n = 1, HBO) vs. control group (n = 8).
Results: The duration of continuous intraumbilical AA/ 
glucose supplementation was 11 (6–13) days. Daily intra-
vascular fetal nutrition significantly prolonged the brain 
sparing to delivery interval by 24 (14–33) days vs. 5.6 (2–12) 
days in controls. Fetal nutrition reduced blood flow resist-
ance in the placental circulation but did not affect the 
Doppler profile of cerebral arteries.  Higher weight gain of 
113.5 (36–539) g was observed following supplementation 
compared to 33.3 (8–98) g in the control group (P< 0.05).  In 
spite of this, fetuses below 28 weeks of gestation did not 
sufficiently benefit from infused commercial AA. We found 
a reduced fetal plasma concentration of the essential AA 
histidine, threonine, lysine and arginine, and non-essential 
AA taurine, in severe IUGR fetuses in both groups. Long-
term supplementation with a commercial AA formula led 
to a slight, but not significant, reduction of histidine, threo-
nine, lysine, arginine, asparagine and glutamine. However, 
the concentration of tryptophan and glutamic acid slightly 
increased. HBO can be combined with AA supplementation 
via a port system. In one case, the port system was also suc-
cessfully used for fetal blood transfusion.
Conclusions: Intravascular treatment of IUGR with fetal 
nutrition can prolong pregnancy with severe placental insuf-
ficiency and brain sparing for many weeks. However, rather 
than normalizing AA concentrations, an enhanced AA 
imbalance was observed in IUGR fetuses following supple-
mentation. These deviations in AA concentrations prevent 
the recommendation for use of commercial AA solutions for 
prenatal treatment of extreme preterm IUGR fetuses.
Keywords: Amino acids; cordocentesis; fetal growth 
restriction; HBO; hyperbaric oxygenation; intraumbilical 
infusion; intrauterine treatment; IUGR; port.
Introduction
Placental insufficiency, the main contributor to the devel-
opment of intrauterine growth restriction (IUGR), is 
caused by numerous factors including chronic placental 
infections, many maternal diseases, abnormal genome 
and intravascular trophoblast invasion impairment [1]. 
Placental insufficiency is responsible for fetal loss in about 
40% of all stillbirths and long-term neurological deficits 
[2–5]. The reduction of blood flow resistance in cerebral 
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arteries in severe IUGR conditions, and reduced pulsatility 
index (PI) in the medial cerebral artery, predicts the 11-fold 
increased risk of intraventricular hemorrhage, periven-
tricular leukomalacia, hypoxic ischemic encephalopathy, 
necrotizing enterocolitis, bronchopulmonary dysplasia, 
sepsis, and death [6]. The mean interval from diagnosis 
of brain sparing to delivery in severe IUGR fetuses was 
recently identified as only 7 days (ranging 2–15 days) [6].
The concentration of amino acids (AA) in fetal plasma 
is many times higher than maternal levels because of 
active transplacental transport of AA and additional AA 
synthesis in the placenta [1, 7].
The critical placental player in the active AA trans-
port from the mother to the fetus is the trophoblast, which 
is irreversibly changed in severe IUGR fetuses caused by 
placental insufficiency [1]. Thus, a logical partial solution 
of IUGR could be the direct supply of AA and glucose to 
the fetus, in order to improve fetal growth, normalize fetal 
programming altered by IUGR and prolong the pregnancy 
[8, 9]. Additional oxygen supply of fetal tissues could also 
improve the uptake of injected nutritional supplements 
and may avoid the development of lactate acidosis in IUGR 
fetuses [10].
The aim of this prospective pilot study was to further 
test the efficacy of the administration of AA and glucose 
via a subcutaneously implanted intraumbilical perinatal 
port system, as a treatment option for severe IUGR human 
fetuses with brain sparing effect.
Materials and methods
Study design
IUGR was defined in our study as an estimated fetal weight of  < 5%, 
(Hadlock-4) combined with increased resistance in both uterine 
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Figure 1: Flow diagram.
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arteries (Ut.A.) with PI  > 95% [11]. Fetuses with morphological 
and/or chromosomal abnormalities were not included in the final 
analysis.
The study commenced in 2010 as a prospective randomized 
clinical trial of patients with intrauterine growth restricted fetuses 
undergoing intraumbilical amino acid and glucose supplemen-
tation, using a subcutaneously implanted port system vs. IUGR 
control patients (NCT02596594, ClinicalTrials.gov). Seventy-eight 
patients were referred to the medical center with IUGR. Fifty-one 
patients did not meet the inclusion criteria of the study. Six patients 
declined participation in the study after explanation of the study 
design and risks of port implantation. Thirteen out of 65 patients 
met the study criteria and gave the permission (Figure 1). The ran-
domisation was performed by institute of Mathematics and Statis-
tics of Martin-Luther University, Halle-Wittenberg, Germany using 
the SPSS statistics program (IBM SPSS Statistics v 20, Ehningen, 
Germany). The study design was restricted to severe IUGR cases 
below 32 weeks’ gestation (WG) with estimated fetal weight  < 3rd 
percentile, pathologic PI > 95% in both Ut.A. and cerebroplacen-
tal ratio  < 1 [CPR = PI MCA/PI umbilical artery (UA)], in response 
to recommendations of Oak Ridge Associated Universities review-
ers (ORAU, Oak Ridge, TN, USA). Due to these restrictions, three 
patients from each group were excluded from final analysis (Fig-
ure 1). We decided to include only patients with severe IUGR and 
CPR < 1 meeting the inclusion criteria from Halle-University, Ger-
many to complete the study in 2014. Thus, six IUGR patients with 
CPR < 1 between 24/0 and 32/0 WG received AA and glucose supple-
mentation via a subcutaneously implanted intraumbilical perinatal 
port system and eight patients with IUGR and brain sparing belong 
to the control group. In response to these restrictions, the study 
became a pilot feasibility study.
The protocol for the port implantation was approved by the insti-
tutional review board (Ethics Committee of National Medical Center 
of the Mother and Child, Nazarbayev University, Astana, N1, 2, 5 and 
6 and Clinical Ethics committee for individual treatment of Martin-
Luther University Halle-Wittenberg, 4th July, 2012). The invasive pro-
cedures were performed with written informed patient  consent.
The ultrasound examinations were performed with Voluson E8 
Expert (GE, Milwaukee, WI, USA) and (Philips iU22, Philips Medical, 
Hamburg, Germany). The monitoring protocol of the study included 
evaluation of amniotic fluid volume, multi-vessel Doppler exami-
nation of the PI in the UA, middle cerebral artery (MCA), Ut.A. and 
ductus venosus at every subsequent contact with research sonogra-
phers until birth. The fetal weight was estimated weekly. A report of 
all sonographic findings was recorded and readily available to the 
clinical physicians using ultrasound software system (Viewpoint, 
GE, USA). The timing of delivery by cesarean section was decided by 
the lead clinician managing each case.
In the control group, fetal blood sampling was performed by 
ultrasound-guided cordocentesis using a 22-gage needle. The blood 
was immediately centrifuged and the serum was frozen in liquid 
nitrogen for AA investigation (high performance liquid chromatogra-
phy, Hewlett Packard Series 1100, Waldbronn, Germany).
Daily hyperbaric oxygenation (100% O2) with a pressure of 1.4 
atmosphere absolute for 50 min (Baromed, Perry Baromedical Cor-
poration, FL, USA) was used in one case, in an attempt to improve 
intraumbilical nutrient supplementation. Additional criteria for pre-
term delivery by C-section were stable pathologic Doppler profiles in 
the DV and/or CTG pathologic findings (variable deep decelerations, 
shot time variations  < 2.9 ms) [12].
Canula Amino acidinfusion
AA
Implanted
port system
Placenta
Uterus
Amniotic cavity
Catheter in situ
Catheter in umbil. vein at the insertion of the umbil. cord
Figure 2: The amino acid and glucose supplementation via a subcu-
taneously implanted intraumbilical port system.
After sonographic localization of the placenta, a small incision into 
the skin with a scalpel was undertaken under local anesthesia with 
20 mL non-adrenalized 1% Xylocaine and a subcutaneous bag for 
the port capsule was prepared using a pair of scissors at the side of 
placental insertion of the cord. The vascular access port capsule was 
flushed with heparinized saline (10 units/mL). The umbilical vein was 
punctured with an 18-gage needle (Echotip® Disposable Trocar Needle, 
COOK Medical, Spencer, IN, USA) under ultrasound control through the 
prepared bag and anterior wall placenta. After fetal blood sampling the 
catheter was inserted through the needle into the umbilical vein with 
a removable 1-French stylet. The port was inserted into the prepared 
bag, where it was fixed with 3-0 Vicryl stitches to the subcutaneous fat 
tissue and the skin was closed with Monocryl 4-0 (ETHICON, Cincin-
nati, OH, USA). Then, the port system was connected to the pump with 
amino acid and glucose solutions. The tip of the 18G needle points on 
the anker system. The treatment course included daily infusions of AA 
and glucose. Note the amniotic cavity remained intact.
Implantation of the port system
Under local anesthesia with 20 mL non-adrenalized 1% xylocaine, a 
small skin incision was made using a scalpel blade. The subcutane-
ous pouch for the port capsule was prepared using a pair of scissors at 
the side of the placental insertion of the cord. The umbilical vein was 
then punctured with an 18-gage needle (Echotip® Disposable Trocar 
Needle, COOK Medical, Spencer, IN, USA) under ultrasound control 
through the prepared pouch and anterior wall placenta ( Figure 2).
The amniotic cavity remained intact during this procedure. 
After fetal blood sampling the catheter was inserted through the nee-
dle into the umbilical vein and connected to the vascular access port 
capsule [8].
The port capsule was fixed with 3-0 Vicryl stitches to the sub-
cutaneous fat tissue and the skin was closed with Monocryl 4-0 
(ETHICON, Cincinnati, OH, USA). A 25-gage port needle was used 
to enter the port system. The treatment course included continuous 
daily infusions of AA solution, Aminoven infant, (n = 4, Fresenius 
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Kabi, Bad Homburg, Germany) or Aminoplasmal B. Braun 10% 
(n = 2, B. Braun, Melsungen, Germany) with a 10% glucose solution. 
We limited the volume of the intraumbilical infusion to 10% of the 
estimated feto-placental blood volume per day [13]. On average, the 
AA/glucose-infusion was below 50 mL/kg. In addition to glucose 
and AAs, fetal supplementation via the port system included insulin 
(1 unit/4 g glucose).
Statistical analysis
The values of the core parameters for the groups were compared using 
an unpaired t-test and multivariate ANOVA. The Doppler parameters 
before and after the fetal nutrition were compared using a paired 
t-test. Data are presented as mean±SD and median (range). P-values 
of  < 0.05 were considered significant. Calculations were performed 
using Statistica® software Version 8.1 (Statsoft, Tulsa, OK, USA).
Results
The port system could be implanted in all patients 
without any complications. The brain sparing to delivery 
interval could be prolonged in the port group to 3 weeks 
(Table 1A and B). The duration of the intraumbilical amino 
acid supplementation was 11 days on average. Fetal nutri-
tion appeared to reduce the resistance to blood flow in the 
placental circulation but did not affect the Doppler profile 
of cerebral arteries (Figure 3A–C).
We found a reduced fetal plasma concentration of 
essential AAs, histidine, threonine, lysine and arginine, 
and non-essential AA taurine, in severe IUGR fetuses in 
both groups [14, 15]. Phenylalanine, glycine, alanine, aspar-
tic acid were slightly increased compared to the normal 
values. The intraumbilical administration of commercial 
AAs via the port system led to a slight but not significant 
reduction of histidine, threonine, lysine and arginine, 
asparagine and glutamine. However, the concentration of 
tryptophan and glutamic acid slightly increased (Table 2).
Intraumbilical AA/glucose supplementation 
increased fetal weight gain (Table 1). The mean weight 
gain remained under the 3rd percentile until delivery, 
except in fetuses below 28 WG, which despite receiving 
sufficient supplementation of 41.3 mL/kg/day on average 
(Table 1A), just failed to gain weight.
In one fetus with 23/3 WG, direct blood supplementa-
tion with 6 mL erythrocyte concentrate at 1 mL/h via the 
port system was required 4  days post-port implantation 
due to suspected fetal anemia in the Doppler ultrasound 
of the MCA Vmax [16]. Feto-maternal hemorrhage could be 
excluded by extremely low concentration of fetal Hb in the 
maternal circulation. The amino acid and glucose infusion 
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Figure 3: (A–C) Dynamic of the pulsatility index in the umbilical artery (UA), middle cerebral artery (MCA) and non-placental uterine artery 
(Ut. A) under  intraumbilical amino acid and glucose supplementation through the subcutaneously implanted port system.
Table 2: Amino acid concentration of severe growth restricted fetuses with brain sparing.
Amino acid (µmol/L) AA/Glucose suplementation via port (mean±SD)   Control (mean±SD)
Port implantation   C-section FBS   C-section
Aspartic acid   18.9±2.9   31.3±11.3   27.3±0.9   26.5±0.5
Glutaminic acid   234.9±176.9   376.0±48.9   372.3±44.3   490.7±50.7
Asparagine   41.0±5.0   35.7±0.9   67.3±5.2   69.3±1.3
Serine   136.2±12.2   140.90±17.9   147.7±0.9   148.3±2.3
Glutamine   355.6±431.7   195.5±9.9   262.0±45.3   218.3±30.7
Histidine   93.4±14.7   77.7±16.5   110.3±7.0   100.3±0.7
Glycine   286.2±71.9   363.0±64.4   290.0±45.2   374.3±23.3
Threonine   284.4±56.7   162.0±10.1   263.3±42.9   315.0±17.0
Citrulline   21.4±2.7   10.7±1.8   23.7±5.2   19.7±0.3
Arginine   56.2±26.2   30.7±22.7   55.7±24.6   42.3±17.7
Alanine   508.9±16.2   471.7±79.2   538.0±60.7   610.0±16.1
Taurine   95.6±9.5   109.7±21.8   64.0±14.2   82.0±0.0
Tyrosine   74.0±3.0   67.3±14.2   63.0±9.3   70±12.0
Aminobutyric acid   25.3±7.5   22.0±5.0   15.0±4.2   16.3±3.3
Valine   218.9±24.9   247.7±40.5   222.0±21.0   214.0±11.0
Methionine   34.0±16.0   20.0±6.1   25.7±9   17.3±9.3
Tryptophane   60.0±1.0   118.7±64.3   66.7±3.8   61.7±1.7
Isoleucine   64±7   71.0±14.7   79.0±3.5   78.3±3.3
Phenylalanine   85.4±4.7   106.7±24.5   91.3±6.9   93.7±6.7
Leucine   106.9±19.9   139.7±31.5   129.7±8.3   132.7±8.7
Lysine   243.7±33.7   222.7±25.7   315.3±40.7   357.3±18.3
Hydroxyproline   52.9±5.2   34.0±2.9   43.0±12.5   37.7±5.7
Proline   236.85±16.2   259.0±41.0   203.3±20.3   202.0±19.0
C-section = Cesarean section, FBS = fetal blood sampling; AA = amino acids. The fetal blood sampling was obtained from the umbilical vein 
during port implantation in the port group or by means of cordocentesis in the control group. The second blood probe was obtained from the 
umbilical vein during the cesarean section in both groups.
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was reduced to 0.1 mL/h after the blood transfusion. The 
Vmax in MCA was normalized to 35.9 cm/s with PI 1.05, 
UA 3.3.1 reversed flow, DV PI 1.42. Intraumbilical nutrition 
was increased to 0.3 mL/h the following day. Ten days 
later, a second transfusion of 6  mL erythrocyte concen-
trate was performed via the port system. The fetus, with an 
estimated weight of 334 g, developed reversed blood flow 
in the DV after 12 days of continuous AA/glucose supple-
mentations (Table 1A). The patient declined an immediate 
delivery by cesarean section, which was recommended 
by our pediatric staff. As expected, an intrauterine fetal 
death occurred the following day and the mother deliv-
ered spontaneously. Pathological examination reported 
an insufficient placenta, measuring only 11 × 7 × 3 cm, with 
a weight of 126 g and infarcts present in about 10% of the 
total placental parenchyma. The position of the catheter 
was found to be optimal without any local hemorrhage. 
The increased Vmax in the CMA was likely a dilution 
effect.
We lost one neonate in the control group from sepsis 
1 week after delivery at 24/4 weeks of gestation. A second 
control group neonate survived sepsis with severe inter-
ventricular hemorrhage grade III/IV. Two extremely 
preterm neonates born at  < 28 weeks gestation from the 
port group, died unexpectedly, 1 week post-delivery (Table 
1A). The low-weight adopted standard care perinatal AA 
nutrition (2.5 g/kg) was given at the intensive care pedi-
atric station. Signs of infection were identified in one of 
these very preterm newborns 4 days after the delivery. One 
newborn in the control group, which was delivered at 32 
WG developed severe cerebral palsy (Table 1B). Impor-
tantly, we tried to improve the AA/glucose supplementa-
tion of IUGR fetuses by hyperbaric oxygenation (1.4 Barr 
absolute for 50 min). We did not find any adverse effects of 
this combined therapy for placental insufficiency on the 
mother nor her baby.
Discussion
In this study, we have demonstrated that a perinatal port 
system for long-term nutrient administration directly into 
the umbilical vein could be successfully implanted into 
all IUGR fetuses with anterior placental location without 
any surgical complications. Flood et  al. presented in 
IUGR PORTO study that the mean interval from diagno-
sis of abnormal cerebroplacental ratio  < 1 to delivery was 
7 days (ranging 2–15 days) [6]. In our study, this interval 
was prolonged by continued nutrient administration via a 
prenatal port system at least three times compared to the 
control group. To our knowledge, this is the first prospec-
tive pilot study for the treatment of human IUGR fetuses 
with severe placental insufficiency and brain sparing, 
using continuous AA and glucose supplementation via 
the subcutaneously implanted intraumbilical port system. 
HBO combined with intraumbilical AA/glucose supple-
mentation was also tested for the first time (n = 1). The 
intrauterine application of AA and glucose into amniotic 
fluid for the treatment of IUGR human fetuses was first 
developed and introduced in the 1970s [17]. Application 
of intra-amniotic AA increased the concentration of AA 
in fetal plasma. Unfortunately, the researchers were faced 
with an increased rate of amnion infection syndrome 
which thwarted this method.
Under physiological conditions, the concentration 
of AA is significantly higher in fetal plasma, compared 
to maternal levels due to active transplacental transport 
of AA and additional AA synthesis in the placenta [1, 7, 
14, 15]. We found unbalanced AA concentrations in the 
plasma of severe IUGR fetuses. Surprisingly, the level of 
glutamic acid was increased but glutamine was dramati-
cally decreased. This phenomenon needs further investi-
gation. Rather than normalizing the AA concentration an 
enhanced AA imbalance was observed in IUGR fetuses 
 following supplementation.
Our protocol was hindered by the proportion of AA 
in commercially available solutions, which differ from 
physiological concentrations. We also encountered every 
low weigh gain in IUGR fetuses below 28 weeks’ gesta-
tional age in spite of daily intraumbilical AA/glucose sup-
plementation of 41.3 mL/kg/day on average (Table  1A). 
Chronic hypoxia of IUGR fetuses leads to the ductus 
venosus sparing with severe reduction of umbilical blood 
perfusion of the fetal liver [18]. It is generally accepted 
that the fetal liver produces proteins, lipids and carbo-
hydrates involved in their metabolism [19–21]. In addi-
tion, the liver synthetizes growth factors, such as insulin 
growth factor (IGF) and its binding proteins (IGFBPs), as 
well as epithelial growth factor, and hepatocyte growth 
factor [20, 21]. The reduction of hepatic blood supply is 
also associated with low IGF-I and -II mRNA expression 
in the fetal liver and significantly reduced cell prolifera-
tion in fetal organs, such as skeletal muscles, heart, liver 
and kidneys [20]. We speculate that the IUGR occurring 
in extremely preterm fetuses, below 28 weeks of gestation 
is harder to overcome with our protocol due to the func-
tional limitations of the fetal liver, combined with blood 
flow by-pass through the DV. The ductus venosus sparing 
would result in significantly reduced umbilical blood 
perfusion of the fetal liver and could be an additional 
key towards the understanding of some methodological 
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restrictions of AA/glucose intraumbilical supplementa-
tions [18].
Additionally, we discovered commercially avail-
able AA solutions have enormous deviations from the AA 
proportions observed in the plasma of preterm fetuses 
(Figure 4) [7, 22, 23]. The commercial AA solutions used in 
our protocol, did not contain asparic acid, glutamic acid, 
glutamine, ornitine (Fresenius), and  cysteine, ornitine, 
glutamine and taurine (B. Braun). Furthermore, these 
solutions had four-fold lower relative concentrations of 
lysine, and threonine, and 25-fold lower relative concen-
tration of taurine, compared to the physiologic AA propor-
tions in the plasma of extreme preterm fetuses (Figure 4).
The AA are not only nutrients, but are also regulators 
of gene expression, the protein phosphorylation cascade, 
cell signaling molecules and hormone synthesis [24]. It is 
highly probable that in extremely preterm infants, long-
term parenteral supplementation with commercial AA 
solutions, which deviate from physiological fetal plasma 
AA concentrations, causes unbalanced plasma AAs in the 
preterm newborn and is partially responsible for worse 
short and long-term outcomes. Norwegian pediatricians 
observed a higher occurrence of septicemia in the very-
low-birth-weight infants (63% vs. 29%) that received an 
enhanced feeding protocol (AA = 3.5 g/kg/day) within 
24  h after birth [25]. In connection with these critically 
important functions of AAs, we assume that long-term 
supplementation with poorly balanced AAs from com-
mercial AA-infusions (in utero and/or postpartum) could 
have led to worse outcomes of extremely preterm infants 
in our pilot study. Lastly, Embleton et  al. underlined an 
extremely limited evidence base of parenteral nutrition 
formulas as the standard-of-care for preterm infants 
despite its widespread use [26]. Clearly, commercial AA 
solutions need to have improved formulation prior to use 
in in fetuses and very preterm neonates.
The intraumbilical infusion appeared to reduce the PI 
in the UA. This could be explained by passive dilatation 
of placental pre-capillaries by increased plasma volume. 
The dilution effect of AA/glucose intraumbilical infusion 
reducing the concentration of norepinephrine and epi-
nephrine may also take part in this pathway. The reaction 
of Ut.A., e.g. spiral arteries, to intraumbilical infusion 
could have other pathways, which need detailed exami-
nations. The advantage of combining HBO with intraum-
bilical amino acid supplementation for IUGR treatment 
via a port system must be proved in future studies. In our 
single participant, we used a low hyperbaric oxygen pres-
sure to avoid up-regulation of the activity of an antioxi-
dant enzyme in the plasma, placenta and fetal brain, and 
to avoid possible oxygen toxicity to the placenta and the 
brain [27].
Figure 4: The commercial amino acid formula concentrations compared with calculated AA concentrations related to very preterm fetuses 
under physiologic conditions.
The commercial AA solutions Aminoven Infant 10% (Fresenius Kabi, Bad Homburg, Germany) and Numeta G 16% (Baxter GmbH, Unter-
schleisshein, Germany) were recommended to pediatricians in Germany by “Rote Liste 2013” [21]. Required fetal AA concentrations were 
estimated using physiological AA-means of very preterm fetuses multiplied by 500 [7, 14, 15].
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Substitution of insufficient placental function with 
supplementary AAs, glucose and oxygen, using a port 
system combined with HBO, could be a therapeutic option 
for placental insufficiency. This would prolong the preg-
nancy, avoid complications associated with very preterm 
birth, reduce under-nutrition, and change the methyla-
tion processes, which induce reprogramming of the fetal 
genome, leading to metabolic syndromes, increased risk 
of coronary heart disease, strokes and diabetes mellitus 
type II [9]. Newborns with IUGR are frequently referred to 
an intensive care department that dramatically increases 
the cost of neonatal treatment [4]. Therefore, prolon-
gation of the pregnancy with fetal nutrition via a port 
system could also provide long-term economic benefit. As 
a matter of course, perinatal specialists must been ade-
quately trained in cordocentesis and port implantation to 
avoid complications related to this method.
We have to address to some limitations of this study. 
We were unable to finish the study as a prospective rand-
omized trial following ORAU recommendations to restrict 
participation to severe IUGR. Due to our limited sample 
size, the study design became a pilot feasibility study. HBO 
was included in our final case after the fetuses  < 28 weeks’ 
gestation failed to respond to AA supplementation. It 
would be interesting to investigate if AA  supplementation 
 contributes to changes in growth factors, insulin and met-
abolic processes in fetal plasma. The large deviation of the 
AA concentrations in fetal plasma reduced the power of 
statistic calculation.
In conclusion, the subcutaneously implanted 
intraumbilical prenatal port system provides long-term 
access to the fetal circulation. This method was success-
fully used in our study for AA/glucose supplementation 
and intrauterine blood transfusion. Combination of HBO 
with AA/glucose supplementation could assist intraum-
bilical nutrient infusion via a port system in cases with 
severe placental insufficiency. Our data suggest that com-
mercial AA formulas, which lack some AA and have large 
deviations from physiologic proportions, are not recom-
mended for the prenatal supplementation of extreme 
preterm IUGR fetuses. Newly formulated AA solutions with 
physiologic plasma AA concentrations, HBO, vitamins, 
trace elements and growth factors are evidently required 
for successful substitution of insufficient placenta in IUGR 
treatment using the subcutaneous port system.
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